



LASA SUPERGENERICS LIMITED

CORPORATE OFFICE: B/207, City Point, Near Kohinoor Hotel, J B Nagar (Chakala) Metro Station, Andheri (E), Mumbai – 400059, Maharashtra, India.

Tel: 022-4970 1092, Email: mail@lasalabs.com, Website: www.lasalabs.com

Ref. No.: LASA/SE/20-21/01

Friday April 03, 2020

To, Corporate Services Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. BSE CODE –540702	To, Corporate Services Department National Stock Exchange of India Limited “Exchange Plaza”, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. NSE CODE: LASA
--	--

Subject: Media Release

Dear Madam/Sir,

Attached is the Copy of Media Release Titled “Lasa pledge to contribute for fight against COVID19” issued by the company.

Kindly take the same on your records.

Thanking you.

Yours faithfully

FOR LASA SUPERGENERICS LIMITED




**NIDHI KULSHRESHTHA
COMPANY SECRETARY & COMPLIANCE OFFICER
M NO.48652**

CIN:L24233MH2016PLC274202

FACTORY & REGD. OFFICE: Plot No. C-105, MIDC, Mahad, Dist. Raigad, Maharashtra, India. Tel: +91-2145-232101/ 232202

Lasa pledge to contribute for fight against COVID 19

Mumbai, April 03, 2020: API major, Lasa Supergenerics Ltd recently announced to Support India's Fight against Corona Virus and pledged support to donate 25000 doses of "Favipiravir" drug to cure Covid19 upon successful clinical trials and requisite approval from Government. Apart from this Company has already extended monetary support to Prime Minister Relief Fund and Chief Minister Relief Fund today.

Commenting on the development, Dr Omkar Herlekar, Chairman– Lasa Supergenerics Limited, said In my opinion "Favipiravir" shall result in one of the best steps in Treatment of COVID19 since Health and safety of our countrymen is of pristine importance Our company today pledged to Donate minimum 25000 doses of "Favipiravir" after success in clinical trials and all statutory nod.

About Favipiravir, Favipiravir is an antiviral drug and is a promising antidote for the treatment of Coronavirus disease (COVID-2019). It possesses activity against many RNA viruses. It is a guanine analogue approved for influenza treatment. It can effectively inhibit the RNA-dependent RNA polymerase of RNA viruses such as influenza, Ebola, yellow fever, chikungunya, norovirus and enterovirus, and a recent study reported its activity against 2019-nCoV.

About Lasa (BSE: 540702; NSE: LASA)

Incorporated in 2011, Lasa is a globally well trusted brand with high quality products, accepted by large companies across the globe. Our Company is the pioneer and amongst the leading players in the manufacturing of Veterinary APIs, with a well-established brand known for its high-quality products amongst various customers. The Company has its unit with state of art manufacturing facilities located at Mahad & Chiplun, Maharashtra with a total installed capacity of 4,300 MT. The Company has over 25% of APIs exported to counties like Australia, Bangladesh, Middle East, China, Turkey, Egypt, Jordan, Korea etc.

For more information contact:

Mr. Hitesh Wadhvani

Lasa Supergenerics Ltd.

Tel: 7798888147

E-mail: hitesh@lasalabs.com